Home Cart Sign in  
Chemical Structure| 122833-04-9 Chemical Structure| 122833-04-9

Structure of 122833-04-9

Chemical Structure| 122833-04-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 122833-04-9 ]

CAS No. :122833-04-9
Formula : C12H19N3O
M.W : 221.30
SMILES Code : NC1=CC=C(N2CCN(C)CC2)C=C1OC
MDL No. :MFCD11848954
InChI Key :LUYPGLRYFIVYTH-UHFFFAOYSA-N
Pubchem ID :20136253

Safety of [ 122833-04-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 122833-04-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 16
Num. arom. heavy atoms 6
Fraction Csp3 0.5
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 73.6
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

41.73 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.27
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.15
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.28
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.82
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.78
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.06

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.08
Solubility 1.83 mg/ml ; 0.00828 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.62
Solubility 5.3 mg/ml ; 0.0239 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.34
Solubility 1.0 mg/ml ; 0.00454 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.83 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.96

Application In Synthesis of [ 122833-04-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 122833-04-9 ]

[ 122833-04-9 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 122833-04-9 ]
  • [ 76661-24-0 ]
  • [ 1213269-25-0 ]
YieldReaction ConditionsOperation in experiment
81% 5-chloro-N-(2-methoxy-4-(4-methyIpiperazin-l-yl)phenyl)-4-(3-nitrophenoxy)pyrimidin- 2-amine A flask was charged with <strong>[76661-24-0]2,5-dichloro-4-(3-nitrophenoxy)pyrimidine</strong> (1.56 g, 5.45 mmol), 2-methoxy-4-(4-methylpiperazin-l-yl)benzenamine (1.21 g, 5.45 mmol), TFA ( 0.42 mL, 5.45 mmol uL), 2-BuOH (30 mL). The slurry was heated to 1000C for 2h. The reaction mixture was allowed to cool to room temperature and, was neutralized with a saturated aqueous sodium bicarbonate solution. The aqueous mixture was then extracted with ethyl acetate (50 mL) three times. The crude product was purified using flash chromatography with 30: 1 :0.3 (v/v/v) dichloromethane-methanol-triethylamine to afford 2.07 g brown solid (81%). 1H NMR 600 MHz (DMSO d6) δ 8.38 (s, IH), 8.28 (s, IH), 8.16 (m, 2H), 7.76 (m, 2H), 7.08 (s, I H), 6.46 (m, IH), 6.14 (m, I H), 3.72 (s, 3H), 3.33 (m, 4H), 3.05 (m, 4H), 2.28 (s, 3H); MS m/z: 471.91 (M+1).
75% With trifluoroacetic acid; In iso-butanol; at 100℃; for 4.0h; General procedure: To a mixture of pyrimidine analogues 34, 35 or 36 (1.56 g, 5.45 mmol), amino piperazine 38 (1.21 g, 5.45 mmol) and anhydrous 2-butanol (30 mL) was added trifluoroacetic acid (0.42 mL, 5.45 mmol). The reaction mixture was heated to 100 C and stirred for 4 h. Subsequently, it was cooled to room temperature and was basified (pH 8.0) by dropwise addition of saturated aqueous sodium bicarbonate solution. The 2-butanol was removed in vacuo to obtain a thick slurry which was dissolved in ethyl acetate (50 mL). The organic layer was washed with water (3 x 20 mL) and brine (1 x 20 mL). The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash silica gel chromatography using dichloromethane-methanol (25:1, v/v) as eluent to afford the nitro analogues as brown solids in yields ranging from 72 - 79%.
72% With trifluoroacetic acid; In iso-butanol; for 5.0h;Reflux; To a solution of <strong>[76661-24-0]2,5-dichloro-4-(3-nitrophenoxy)pyrimidine</strong> (0.9 g, 3.16 mmol), 2-methoxy-4-(4-methylpiperazin-1-yl)benzenamine (0.7 g, 3.16 mmol), in 2-butanol (20 mL) was added trifluoroacetic acid (0.25 mL, 3.16 mmol). The resultant slurry was refluxed for 5 hours. The reaction mixture was allowed to cool to room temperature and then was neutralized with a saturated aqueous sodium bicarbonate solution. The aqueous mixture was then extracted with ethyl acetate (3*500 mL) and the combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to furnish an oil which was purified by column chromatography on silica gel (100-200 mesh) eluting with 2-3% (v/v) methanol in dichloromethane to produce as pale brown solid (1 g, yield 72%). 1H NMR 400 MHz (DMSO-d6) δ 8.37 (s, 1H), 8.29 (s, 1H), 8.17-8.16 (m, 2H), 7.75-7.74 (m, 2H), 7.08-7.06 (m, 1H), 6.48 (s, 1H), 6.14 (s, br, 1H), 3.69 (s, 3H), 3.03 (t, J=4.8 Hz, 4H), 2.46 (t, J=4.8 Hz, 4H), 2.23 (s, 3H); LCMS m/e: 471 [M+1]+.
65% With trifluoroacetic acid; In butan-1-ol; at 100℃; for 18.0h; To a solution of compound 8 (1.33 g, 4.66 mmol) and compound11 (1.03 g, 4.66 mmol) in anhydrous 1-butanol (20 mL), trifluoroacetic acid (0.36 mL, 4.66 mmol) was added. The reaction mixturewas heated to 100 C and stirred for 18 h. Subsequently, it wascooled to room temperature and saturated aqueous sodium bicarbonatesolution was added drop wise until basic pH was obtained.The volatiles were removed in vacuo and the obtained thick slurrywas dissolved in DCM (50 mL). The organic layer was washed withwater (20 mL), brine (20 mL), dried over anhydrous sodium sulfate,filtered and concentrated in vacuo. The crude was purified by flashsilica gel chromatography using DCM/MeOH (96:4, v/v) as eluentto afford 1.42 g of the desired product 12 (3.02 mmol, 65%) as white solid.

  • 2
  • [ 122833-04-9 ]
  • [ 64837-49-6 ]
  • [ 1313036-60-0 ]
YieldReaction ConditionsOperation in experiment
25% With toluene-4-sulfonic acid; In Isopropyl acetate; at 80℃; Ethyl 5-chloro-l ,3,4-thiadiazole-2 -carboxylate (3, 3 g, 15.7 mmol), 2-methoxy-4-(4-methyl piperazin-l -yl)aniline (4, 3.4 g, 15.7 mmol) and p-TSA (3 g, 15.7 mmol) were taken up in IPA (25 mL) and the resultant mixture was stirred at 80 C overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, the solvent was evaporated from the reaction mixture under reduced pressure, and the resultant residue was basified using aq. NaHC03 solution and extracted with ethyl acetate. The organic extract was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The resultant crude product was purified by columnchromatography using 5% MeOH-DCM to afford ethyl 5-((2-methoxy-4-(4-methylpiperazin-l - yl)phenyl)amino)-l ,3,4-thiadiazole-2-carboxylate (5, 1 .5 g, 25%). NMR (400 MHz, CDC13): delta 7.90 (bs, 1 H), 7.43 (d, 1 H), 6.59-6.55 (m, 2H), 4.50 (q, 2H), 3.90 (s, 3H), 3.25-3.22 (m, 4H), 2.65- l .60 (m, 4H), 2.40 (s, 3H), 1.42 (t, 3H).
  • 3
  • [ 122833-04-9 ]
  • [ 1197953-49-3 ]
  • (2-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 122833-04-9 ]

Aryls

Chemical Structure| 1011-17-2

A895756 [1011-17-2]

2-(Piperazin-1-yl)phenol

Similarity: 0.87

Chemical Structure| 761440-75-9

A158305 [761440-75-9]

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.86

Chemical Structure| 1254058-34-8

A268760 [1254058-34-8]

3-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.85

Chemical Structure| 83763-47-7

A119412 [83763-47-7]

2-((3-Amino-4-methoxyphenyl)amino)ethanol

Similarity: 0.85

Chemical Structure| 20440-94-2

A148466 [20440-94-2]

4-Methoxy-N-(4-methoxyphenyl)-N-phenylaniline

Similarity: 0.84

Ethers

Chemical Structure| 761440-75-9

A158305 [761440-75-9]

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.86

Chemical Structure| 1254058-34-8

A268760 [1254058-34-8]

3-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.85

Chemical Structure| 83763-47-7

A119412 [83763-47-7]

2-((3-Amino-4-methoxyphenyl)amino)ethanol

Similarity: 0.85

Chemical Structure| 20440-94-2

A148466 [20440-94-2]

4-Methoxy-N-(4-methoxyphenyl)-N-phenylaniline

Similarity: 0.84

Chemical Structure| 59194-26-2

A487787 [59194-26-2]

5-Methoxy-2-(1H-pyrrol-1-yl)aniline

Similarity: 0.83

Amines

Chemical Structure| 761440-75-9

A158305 [761440-75-9]

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.86

Chemical Structure| 1254058-34-8

A268760 [1254058-34-8]

3-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.85

Chemical Structure| 83763-47-7

A119412 [83763-47-7]

2-((3-Amino-4-methoxyphenyl)amino)ethanol

Similarity: 0.85

Chemical Structure| 20440-94-2

A148466 [20440-94-2]

4-Methoxy-N-(4-methoxyphenyl)-N-phenylaniline

Similarity: 0.84

Chemical Structure| 59194-26-2

A487787 [59194-26-2]

5-Methoxy-2-(1H-pyrrol-1-yl)aniline

Similarity: 0.83

Related Parent Nucleus of
[ 122833-04-9 ]

Piperazines

Chemical Structure| 1011-17-2

A895756 [1011-17-2]

2-(Piperazin-1-yl)phenol

Similarity: 0.87

Chemical Structure| 761440-75-9

A158305 [761440-75-9]

2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.86

Chemical Structure| 1254058-34-8

A268760 [1254058-34-8]

3-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline

Similarity: 0.85

Chemical Structure| 74853-08-0

A479529 [74853-08-0]

1-(4-Aminophenyl)-4-(4-hydroxyphenyl)piperazine

Similarity: 0.82

Chemical Structure| 56621-48-8

A278499 [56621-48-8]

4-(Piperazin-1-yl)phenol

Similarity: 0.82